SOD3 Genotype

Most of the antioxidant defense in your blood vessels and the fluid around your cells comes from a single enzyme, and your SOD3 (extracellular superoxide dismutase) genotype sets how much of it your body makes and where it ends up. Common inherited variants in this gene can raise circulating levels of the enzyme roughly tenfold, shift lung function across whole populations, and tilt heart attack risk in people with diabetes.

This is still a research-stage marker rather than a guideline-driven test, so a single result will not slot you neatly into a risk bucket the way LDL or HbA1c would. The value is locking in your inherited starting point now, so that as you make long-term decisions about cardiovascular, metabolic, and lung health, you and your clinician are working from your own DNA rather than population averages.

What the Gene Actually Does

SOD3 encodes an enzyme called extracellular SOD, or EC-SOD. After it is made, the protein is secreted into plasma and the matrix that holds your tissues together, where it converts a reactive molecule called superoxide into hydrogen peroxide and oxygen. The enzyme is especially concentrated in arterial walls, where it accounts for a large share of antioxidant SOD activity, and it helps regulate how much nitric oxide is available to keep blood vessels relaxed.

Several inherited variants are commonly studied. The most prominent is R213G (also written as p.R231G or rs1799895), which sits in the part of the protein that normally anchors it to tissue. Carriers release more of the enzyme into the bloodstream, with plasma levels reported at roughly ten times higher than non-carriers in heterozygotes and ten to thirty times higher in homozygotes, but less of it sticks to vessel walls where it usually works. Other variants include a promoter variant (rs2284659), regulatory variants in the 5′ region and first intron known as E1 and I1 (rs8192287 and rs8192288), and the missense variants rs2536512 and rs2855262, which change single amino acids in the protein and have been associated with altered enzyme activity.

Lung Function and COPD Resistance

Two large population studies, with a combined sample size of about 44,000 adults, found that people who carried two copies of the E1 or I1 variants had measurably lower forced vital capacity (the maximum amount of air they could exhale) than non-carriers, on the order of several percent. The same variants tracked with higher rates of COPD hospitalization, and a directionally similar but borderline-significant signal for COPD mortality. A separate analysis of smokers found the 213Gly version of R213G was significantly more common in "resistant smokers" who never developed COPD, with carriers roughly four times more likely to be in the resistant group than the COPD group. The picture for R213G is not uniformly protective: heterozygotes appear protected against smoking-related COPD, but rare R213G homozygotes in never-smokers have been reported to have substantially lower FEV1, so direction of effect can depend on smoking exposure and gene dose.

What this means for you: if you have a smoking history or persistent respiratory symptoms, an SOD3 result is one of several inherited inputs that can frame how aggressively you should pursue spirometry and lung surveillance. It does not change the core advice of quitting and monitoring, but it can shape urgency.

Cardiovascular Risk When You Have Diabetes

This is where SOD3 has shown some of its sharpest signals. In a Danish analysis of about 96,000 people, those with diabetes who carried one copy of R213G had more than twice the rate of cardiovascular events and heart failure compared to non-carriers with diabetes (hazard ratio around 2.3). The variant did not raise risk in people without diabetes, suggesting it matters mainly when the vascular system is already under metabolic stress.

A separate cohort of about 4,200 adults with type 1 or type 2 diabetes looked at a different SOD3 variant. People carrying the T-allele of rs2284659 had higher plasma EC-SOD, lower oxidative stress markers, and roughly 42% lower rates of heart attack during follow-up (hazard ratio 0.58), with similar reductions in cardiovascular and all-cause mortality.

What this means for you: if you have diabetes, pre-diabetes, or strong insulin resistance, your SOD3 genotype can sharpen how aggressively you and your clinician target the standard risk factors. The variant itself does not need treatment, but a high-risk SOD3 result raises the stakes of every other cardiovascular metric you can move.

Triglycerides and HDL

In a study of 396 people at high risk of coronary disease, carriers of the AA genotype at rs2536512 or the CC genotype at rs2855262 had increased odds of the combination of high triglycerides and low HDL cholesterol, the pattern often called atherogenic dyslipidemia. The risk grew when SOD3 variants were stacked with related antioxidant gene variants, pointing to a polygenic rather than single-gene effect.

Why More Antioxidant Is Not Always Better

At first glance, anything that raises an antioxidant enzyme should be good. The evidence on SOD3 does not work that way. R213G carriers pour more SOD3 into the bloodstream but bind less of it to vessel walls, so the same variant looks protective in smokers' lungs and harmful in diabetic blood vessels. In adults over 85, those with higher plasma EC-SOD (in non-carriers of p.R231G) had higher odds of chronic kidney disease and lower odds of diabetes. SOD3 is not a simple "good number, bad number" marker. It signals a different distribution of antioxidant activity between blood and tissue, and the consequences depend on which tissue is under stress at a given moment of your life.

A One-Time Result

Your SOD3 genotype was set at conception and does not change. You do not retest it. The value of this single test is feeding the result into ongoing decisions for the rest of your life. If you carry a risk-associated variant, the right next step is closer surveillance of the systems where it matters: an ApoB-based lipid panel, Lp(a), HbA1c, blood pressure, and spirometry if you have any smoking exposure. Those dynamic markers should be retested at least annually, and more often if you are actively changing diet, training, or medication.

What to Do With an Out-of-Pattern Result

A SOD3 result by itself does not trigger treatment. It should trigger a more focused workup of the systems where the variant has measurable effects. If you carry R213G and have diabetes, pre-diabetes, or strong insulin resistance, that pairing argues for an aggressive cardiovascular workup with an ApoB-based lipid panel, Lp(a), HbA1c, and a conversation with a preventive cardiologist or lipidologist about lower LDL targets. If you carry the E1 or I1 variants and have any smoking history, push for baseline and serial spirometry rather than waiting for symptoms. If you carry dyslipidemia-associated variants and your triglycerides and HDL are already drifting in the wrong direction, treat the lipid pattern earlier rather than letting it sit.

Genetic counseling is reasonable if the result intersects with a strong family history of early heart attack, stroke, or COPD, because the conversation extends to first-degree relatives who may share the variant.

When Results Can Be Misleading

• Variant panel coverage: this test detects only the specific SOD3 variants the assay was designed to read. A "negative" result does not mean you carry no SOD3 variants, only that none of the targeted ones were found.
• Population frequency: some SOD3 variants are common in one ancestry group and rare in another. Reported frequencies for the same variant can also vary across cohorts, so population context matters for how seriously to weigh a finding.
• Variants of uncertain significance: an SOD3 result may flag a variant whose clinical meaning is not yet established. This reflects the current state of evidence, not a problem with your sample.
• Direct-to-consumer comparisons: if you have seen an SOD3 SNP on a 23andMe-style report, the chip technology and reporting standards differ from clinical-grade genotyping. Confirming a high-stakes variant on a clinical test is reasonable.